Open access · US-GOV
via ClinicalTrials.gov Clinical trial
CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging
Authors not listed
Huashan Hospital · 2023
Abstract
To explore the diagnostic value of \[18F\]CSF-23 brain imaging for CSF1R expression in Alzheimer's disease. PET imaging with this PET tracer was used to assess the role and expression of CSF1R in AD and to evaluate the level and safety of abnormal present imaging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2023). CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging. <em>Huashan Hospital</em>. https://clinicaltrials.gov/study/NCT06148233
Vancouver
Anonymous. CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging. Huashan Hospital. 2023.
BibTeX
@misc{anon2023CSFRPE,
title = {CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging},
author = {Anonymous},
journal = {Huashan Hospital},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Annals of Neurology 2011
Preprint · OA
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease
Val Lowe 2021
Open access · US-GOV
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
Springer eBooks 2018
Citation only
Sirtuin Modulators and Brain Aging
Journal of Experimental & Clinical Medicine 2014
Preprint · CC-BY
Epigenomics of Alzheimer's Disease
Invicro 2018
Open access · US-GOV
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Navidea Biopharmaceuticals 2012
Open access · US-GOV